| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop
|
Lorigan, P.
|
|
|
30 |
7 |
p. 1038-1040
|
artikel
|
| 2 |
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
|
Matulonis, U.A.
|
|
|
30 |
7 |
p. 1080-1087
|
artikel
|
| 3 |
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
|
Kelly, R.J.
|
|
|
30 |
7 |
p. 1127-1133
|
artikel
|
| 4 |
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
|
Matikas, A.
|
|
|
30 |
7 |
p. 1044-1050
|
artikel
|
| 5 |
Circulating tumor cells are prognostic in SCLC, but still lack clinical application
|
Tamminga, M.
|
|
|
30 |
7 |
p. 1031-1033
|
artikel
|
| 6 |
Corrections to “Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis”
|
Cortes, J.
|
|
|
30 |
7 |
p. 1179
|
artikel
|
| 7 |
Corrections to “De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017”
|
Curigliano, G.
|
|
|
30 |
7 |
p. 1181
|
artikel
|
| 8 |
Corrections to “PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab”
|
Loibl, S.
|
|
|
30 |
7 |
p. 1180
|
artikel
|
| 9 |
Corrections to “Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors”
|
Serrano, C.
|
|
|
30 |
7 |
p. 1178
|
artikel
|
| 10 |
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
|
Shaw, A.T.
|
|
|
30 |
7 |
p. 1121-1126
|
artikel
|
| 11 |
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
|
Jansen, Y.J.L.
|
|
|
30 |
7 |
p. 1154-1161
|
artikel
|
| 12 |
Early-phase clinical drug development of novel agents: a changing paradigm
|
de Miguel, M.
|
|
|
30 |
7 |
p. 1033-1037
|
artikel
|
| 13 |
Editorial board
|
|
|
|
30 |
7 |
p. ii-iii
|
artikel
|
| 14 |
Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis
|
Rota, M.
|
|
|
30 |
7 |
p. 1040-1043
|
artikel
|
| 15 |
Hyperprogression during immunotherapy: do we really want to know?
|
Champiat, S.
|
|
|
30 |
7 |
p. 1028-1031
|
artikel
|
| 16 |
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
|
Kim, C.G.
|
|
|
30 |
7 |
p. 1104-1113
|
artikel
|
| 17 |
Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
|
Gaillard, S.L.
|
|
|
30 |
7 |
p. 1025-1028
|
artikel
|
| 18 |
Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection
|
Ros, J.
|
|
|
30 |
7 |
p. 1173-1177
|
artikel
|
| 19 |
Interactions between direct anticoagulants and chemotherapy
|
Sorigue, M.
|
|
|
30 |
7 |
p. 1170
|
artikel
|
| 20 |
Journey’s end: the quest for BRCA-like hereditary breast cancer genes is nearly over
|
Foulkes, W.D.
|
|
|
30 |
7 |
p. 1023-1025
|
artikel
|
| 21 |
Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications
|
Witte, J.
|
|
|
30 |
7 |
p. 1061-1070
|
artikel
|
| 22 |
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
|
Hellmann, M.D.
|
|
|
30 |
7 |
p. 1134-1142
|
artikel
|
| 23 |
Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial
|
Tay, R.Y.
|
|
|
30 |
7 |
p. 1114-1120
|
artikel
|
| 24 |
Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy
|
Pastorino, U.
|
|
|
30 |
7 |
p. 1162-1169
|
artikel
|
| 25 |
Rare cancers: from centralized referral to networking
|
Casali, P.G.
|
|
|
30 |
7 |
p. 1037-1038
|
artikel
|
| 26 |
RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor
|
Jouenne, F.
|
|
|
30 |
7 |
p. 1170-1172
|
artikel
|
| 27 |
Surgery in reference centers improves survival of sarcoma patients: a nationwide study
|
Blay, J.-Y.
|
|
|
30 |
7 |
p. 1143-1153
|
artikel
|
| 28 |
Table of Contents
|
|
|
|
30 |
7 |
p. iv-vi
|
artikel
|
| 29 |
Targeting the PI3-kinase pathway in triple-negative breast cancer
|
Pascual, J.
|
|
|
30 |
7 |
p. 1051-1060
|
artikel
|
| 30 |
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
|
Hamfjord, J.
|
|
|
30 |
7 |
p. 1088-1095
|
artikel
|
| 31 |
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
|
Schrock, A.B.
|
|
|
30 |
7 |
p. 1096-1103
|
artikel
|
| 32 |
Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers
|
Nones, K.
|
|
|
30 |
7 |
p. 1071-1079
|
artikel
|
Tijdschrift beschrijving